Vilacto Bio Inc. Upgraded facility, output with an

COPENHAGEN, Denmark, July 14, 2017 (GLOBE NEWSWIRE) -- Vilacto Bio Inc. (OTC QB:VIBI), is pleased to announce that the upgrade of its production facility was completed this week. The upgrade has been in process the last 6 weeks and has included an additional storage container, improved mixing machines and upscale filtration unit. The upgrade allows Vilact Bio Inc to increase its production of its Lactoactive ^® molecule and output with an estimated 300% which the company anticipates will be needed as a part of the new range of products that is being launched this fall.

“This is another important step in our evolution as a skin care and Biotech Company and we are pleased to make this announcement," states Gert Anderson, CEO of Vilacto Bio Inc.

About Vilacto Bio Inc.: Vilacto Bio Inc. (OTC QB:VIBI), is a biotech company that has developed the now fully patented Lactoactive ^® (Lactoactive molecule) that in numerous studies has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. We aim to further develop our Lactoactive ^® molecule for the purpose of increasing the quality of our retail and medical skin cream products as well as licensing out our Lactoactive ^® molecule for the pharmaceutical industry.

Find out about Vilact on instagram https://www.instagram.com/vilact_com/  and facebook https://da-dk.facebook.com/skincare.vilact/ .

Vilacto Bio Inc. The Seagram Building 375 Park Avenue, Suite 2607 New York City, NY 10152 Gert Andersen Phone: +1 646-893-7895 info@vilactobio.com www.vilactobio.com Source: Vilacto Bio Inc.